F. Hoffmann-La Roche AG
Company History
Roche History: Founding, Growth & Key Milestones
Founded 1896 in Basel, Switzerland
When was Roche founded?
Roche was founded in 1896 in Basel, Switzerland by Fritz Hoffmann-La Roche, making it 130 years old.
- Founded
- 1896
- Founding place
- Basel, Switzerland
- Founders
- Fritz Hoffmann-La Roche
- Headquarters today
- Basel, Switzerland
- Milestones documented
- 12 (1896–2025)
- Current CEO
- Thomas Schinecker
- Acquisitions
- 10
| Year | Event |
|---|---|
| 1896 | F. Hoffmann-La Roche Founded in Basel |
| 1898 | Commercial Breakthrough with Sirolin |
| 1934 | First Industrial Synthesis of Vitamin C |
| 1963 | Launch of Valium (Diazepam) |
| 1968 | Establishment of Roche Diagnostics |
| 1990 | Majority Stake in Genentech |
| 1997 | Boehringer Mannheim Acquired |
| 2008 | Severin Schwan becomes CEO |
| 2009 | Full Acquisition of Genentech for $46.8 Billion |
| 2018 | Foundation Medicine & Flatiron Health Acquisitions |
| 2023 | Acquired Telavant |
| 2025 | Group Sales Reach CHF 61.5 Billion |
- Where was Roche founded?
- Roche was founded in Basel, Switzerland in 1896. wikidata.org
- Who founded Roche?
- Roche was founded by Fritz Hoffmann-La Roche.
- When did Roche start?
- Roche was founded in 1896.
- How old is Roche?
- Roche is 130 years old as of 2026.
Founding Story
Fritz Hoffmann-La Roche founded the company in Basel in 1896 to produce standardized medicines on an industrial scale. Early successes such as the cough syrup Sirolin funded foreign expansion. Roche later became a major vitamin producer after acquiring rights to Tadeus Reichstein's vitamin C synthesis in the 1930s, and benzodiazepines Librium (1960) and Valium (1963) made it one of the most profitable drugmakers of the post-war era.
Founders
Fritz Hoffmann-La Roche
Fritz Hoffmann-La Roche (1868-1920) founded F. Hoffmann-La Roche & Co. in Basel on 1 October 1896, at age 28. His idea was to manufacture standardized, branded medicines industrially and sell them internationally rather than rely on pharmacist-compounded remedies. Early products included the thyroid preparation Thyreoglandol, the cough syrup Sirolin and the digitalis extract Digalen. He opened foreign subsidiaries within a few years of founding, giving Roche an international footprint long before most competitors. Friedrich "Fritz" Hoffmann-La Roche was born on October 24, 1868 and died on April 18, 1920. Fritz Hoffmann-La Roche was born in 1868.
Key Milestones
F. Hoffmann-La Roche Founded in Basel
Fritz Hoffmann-La Roche founds the enterprise in Basel, Switzerland, pioneering mass-manufactured, chemically standardized prescription pharmaceuticals.
Source: en.wikipedia.orgCommercial Breakthrough with Sirolin
Roche launches non-prescription cough syrup Sirolin, achieving widespread international distribution and financing early clinical laboratories.
Source: en.wikipedia.orgFirst Industrial Synthesis of Vitamin C
Roche becomes the first company to mass-produce synthetic Vitamin C (Redoxon) at industrial scale, anchoring decades of high-margin global cash flow.
Source: en.wikipedia.orgLaunch of Valium (Diazepam)
Roche introduces Valium, which becomes the world's most widely prescribed psychotropic medication and establishes global pharmaceutical leadership.
Source: en.wikipedia.orgEstablishment of Roche Diagnostics
Roche launches its dedicated diagnostic division, laying the foundation to become the world's preeminent in-vitro diagnostics (IVD) provider.
Source: en.wikipedia.orgMajority Stake in Genentech
Roche bought a majority stake in Genentech in 1990.
Source: en.wikipedia.orgBoehringer Mannheim Acquired
Roche bought Corange, the parent of Boehringer Mannheim, in 1997 for about $11 billion.
Source: en.wikipedia.orgSeverin Schwan becomes CEO
Severin Schwan became CEO of F. Hoffmann-La Roche in 2008. Led Roche for 14 years; handed over to Thomas Schinecker in March 2023 and became chairman.
Source: biopharmadive.comFull Acquisition of Genentech for $46.8 Billion
Roche completes its historic $46.8 billion buyout of American biotechnology pioneer Genentech, securing market leadership in oncology biologics.
Source: en.wikipedia.orgFoundation Medicine & Flatiron Health Acquisitions
Roche acquires Foundation Medicine and Flatiron Health, integrating real-world oncology data analytics and genomic profiling into personalized healthcare.
Source: en.wikipedia.orgAcquired Telavant
F. Hoffmann-La Roche acquired Telavant for $7.1 billion. Roche paid $7.1 billion upfront for Telavant to gain US and Japan rights to the anti-TL1A antibody RVT-3101 (afimkibart) for inflammatory bowel disease.
Source: roche.comGroup Sales Reach CHF 61.5 Billion
Under CEO Thomas Schinecker, Roche delivers group sales of ~$73.8 billion (CHF 61.5 billion), driven by ~$57.2B (CHF 47.7B) in Pharmaceuticals and ~$16.6B (CHF 13.8B) in Diagnostics.
Source: roche.comMajor Acquisitions
Biomedical Reference Laboratories
1982F. Hoffmann-La Roche acquired Biomedical Reference Laboratories in 1982 for $164 million.
Genentech
2009Roche bought the roughly 44% of Genentech it did not already own for about $46.8 billion, after holding a majority stake since 1990.
Bina Technologies
2014F. Hoffmann-La Roche acquired Bina Technologies in 2014.
Adheron Therapeutics
2015F. Hoffmann-La Roche acquired Adheron Therapeutics in 2015 for $105 million.
ForSight VISION4
2017F. Hoffmann-La Roche acquired ForSight VISION4 in 2017.
Foundation Medicine
2018Roche bought the remaining shares of Foundation Medicine it did not own, in a deal valued at about $2.4 billion, to add comprehensive genomic profiling.
Telavant
2023Roche paid $7.1 billion upfront for Telavant to gain US and Japan rights to the anti-TL1A antibody RVT-3101 (afimkibart) for inflammatory bowel disease.
Carmot Therapeutics
2023Roche paid $2.7 billion upfront for Carmot to enter obesity, adding the incretin candidate CT-388 (enicepatide).
89bio
2025Roche agreed in September 2025 to buy 89bio for $14.50 per share in cash plus a CVR of up to $6.00 per share, a total of up to about $3.5 billion, adding the MASH candidate pegozafermin.
PathAI
2026Roche agreed in May 2026 to acquire Boston-based PathAI for $750 million upfront plus up to $300 million in milestones to strengthen AI-driven digital pathology.
Keep researching Roche
Roche Company History FAQ
When and where was Roche founded?
F. Hoffmann-La Roche & Co. was founded on October 1, 1896, in Basel, Switzerland, by entrepreneur Fritz Hoffmann-La Roche.
What was Roche's original commercial breakthrough product?
In 1898, Roche launched "Sirolin," a non-prescription orange-flavored cough syrup containing the active ingredient thiocol, which became a global commercial hit and established Roche's international reputation.
How did Roche pioneer mass industrial vitamin production?
In 1934, Roche became the first company in the world to mass-produce synthetic Vitamin C (under the brand name Redoxon), followed by industrial synthesis of Vitamin A, Vitamin B, and Vitamin E, becoming the dominant global vitamin supplier for decades.
What was Roche's breakthrough in psychotropic medications in the 1960s?
Chemist Leo Sternbach discovered the benzodiazepine class of tranquilizers at Roche's Nutley, New Jersey research laboratory, leading to the commercial launches of Librium (1960) and Valium (1963), the latter becoming the world's bestselling prescription drug.
When did Roche acquire Genentech and why was it historic?
Roche acquired a majority 60% stake in biotechnology pioneer Genentech in 1990 for $2.1 billion, and acquired the remaining 40% in March 2009 for $46.8 billion in one of the most successful pharmaceutical takeovers in history, transforming Roche into the world's oncology powerhouse.
What blockbuster cancer drugs did Roche acquire through Genentech?
The Genentech acquisition gave Roche exclusive global rights to historic monoclonal antibody blockbusters: Rituxan/MabThera (lymphoma), Herceptin (HER2+ breast cancer), and Avastin (angiogenesis inhibitor for colorectal/lung cancer).
How did Roche become the global leader in molecular diagnostics?
In 1991, Roche acquired the worldwide patent rights to the Polymerase Chain Reaction (PCR) technology from Cetus Corporation for $300 million, laying the foundation for modern molecular diagnostics and automated viral load testing (HIV, Hepatitis).
What happened to Roche's historical vitamin division?
In 2003, Roche divested its historic Vitamins and Fine Chemicals division to Dutch life sciences company DSM for €2.25 billion, refocusing capital exclusively on high-margin pharmaceuticals and diagnostics.
How did Roche respond to the COVID-19 pandemic?
Under then-Diagnostics CEO Thomas Schinecker, Roche rapidly developed and received FDA Emergency Use Authorization for the first commercial high-throughput molecular test (cobas SARS-CoV-2), deploying tens of millions of PCR and rapid antigen tests worldwide.
What family controls the voting shares of Roche today?
The descendants of founder Fritz Hoffmann-La Roche (the Hoffmann-Oeri-Duschmalé family pool) hold a controlling voting majority of approximately 50.1% of Roche's bearer voting shares, ensuring multi-generational strategic independence.
What major multi-billion-dollar deals did Roche execute in 2023?
In late 2023, Roche acquired Telavant for $7.1 billion (securing promising Phase 3 IBD antibody RVT-3101) and agreed to acquire Carmot Therapeutics for $2.7 billion, entering the booming anti-obesity and diabetes GLP-1/GIP drug market.
Who leads Roche as Chief Executive Officer today?
Thomas Schinecker became CEO of the Roche Group in March 2023, succeeding long-time CEO Severin Schwan, who transitioned to Chairman of the Board of Directors.
Related Companies
Compare F. Hoffmann-La Roche AG History With Competitors
Related Strategic History
Compare founding milestones and corporate evolution
Explore Roche
Core profile pages, founders and related research hubs for this company.